Developing potent and selective small molecule WDR5 inhibitors for the treatment of leukemias and solid tumours
Related news
FACIT Announces Investment in Propellon Therapeutics
Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers. Read More
Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers
The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships. Read More
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia. Read More
FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia. Read More
